Literature DB >> 3429853

Detection of postvaccination mumps virus antibody by neutralization test, enzyme-linked immunosorbent assay and sensitive hemagglutination inhibition test.

D Fedová1, M Brůcková, V Plesník, D Slonim, J Sejda, E Svandová, I Kubínová.   

Abstract

A group of 251 children aged 2-3 years given live attenuated mumps virus vaccine PAVIVAC of Czechoslovak production were tested for antiparotitis antibody levels in pre- and postvaccination sera by neutralization test (NT), enzyme-linked immunosorbent assay (ELISA) and sensitive hemagglutination inhibition test, enhanced by heterologous antibody to human immunoglobulin G (E-HIT). The prevaccination findings were as follows: positive ELISA IgG titres, neutralization antibodies and hemagglutination inhibition antibodies were present in, respectively, 35%, 25.9% and 27.9% of the sera. Postvaccination seroconversions were evaluated in 159 susceptible vaccinees whose prevaccination sera had been negative by all three tests. The lowest seroconversion was detected by NT (74.2%), seroconversions by ELISA and E-HIT were appreciably higher (82.4% and 86.8%, respectively). The seven children showing a seroconversion by E-HIT but not by ELISA had a 4 fold increase of anti-mumps ELISA IgG antibodies as well, but the rise of antibody titres was at a level falling in the range below the positivity criterion for ELISA. The statistically evaluated detection rate for antibodies was significantly higher (significance test "t") by ELISA as compared with neutralization test. However, antibody levels (geometric mean titres) were 8-10 times lower in postvaccination sera than in convalescent sera of 30 children with mumps in all three tests.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3429853

Source DB:  PubMed          Journal:  J Hyg Epidemiol Microbiol Immunol        ISSN: 0022-1732


  7 in total

1.  Evaluation of two enzyme immunoassays for detection of immunoglobulin G antibodies to mumps virus.

Authors:  J L Backhouse; H F Gidding; P B McIntyre; G L Gilbert
Journal:  Clin Vaccine Immunol       Date:  2006-07

2.  Standardization of measles, mumps and rubella assays to enable comparisons of seroprevalence data across 21 European countries and Australia.

Authors:  A Tischer; N Andrews; G Kafatos; A Nardone; G Berbers; I Davidkin; Y Aboudy; J Backhouse; C Barbara; K Bartha; B Bruckova; A Duks; A Griskevicius; L Hesketh; K Johansen; L Jones; O Kuersteiner; E Lupulescu; Z Mihneva; M Mrazova; F De Ory; K Prosenc; F Schneider; A Tsakris; M Smelhausova; R Vranckx; M Zarvou; E Miller
Journal:  Epidemiol Infect       Date:  2007-03-30       Impact factor: 2.451

Review 3.  Mumps: an Update on Outbreaks, Vaccine Efficacy, and Genomic Diversity.

Authors:  Eugene Lam; Jennifer B Rosen; Jane R Zucker
Journal:  Clin Microbiol Rev       Date:  2020-02-26       Impact factor: 26.132

4.  Mumps virus-specific antibody titers from pre-vaccine era sera: comparison of the plaque reduction neutralization assay and enzyme immunoassays.

Authors:  Jeremy Mauldin; Kathryn Carbone; Henry Hsu; Robert Yolken; Steven Rubin
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

5.  Differential durability of immune responses to measles and mumps following MMR vaccination.

Authors:  Richard B Kennedy; Inna G Ovsyannikova; Antonia Thomas; Beth R Larrabee; Steven Rubin; Gregory A Poland
Journal:  Vaccine       Date:  2019-02-20       Impact factor: 3.641

6.  In vitro and in vivo growth alter the population dynamic and properties of a Jeryl Lynn mumps vaccine.

Authors:  Sarah M Connaughton; Jun X Wheeler; Eva Vitková; Philip Minor; Silke Schepelmann
Journal:  Vaccine       Date:  2015-07-15       Impact factor: 3.641

7.  Is vaccine type seropositivity a marker for human papillomavirus vaccination? National Health and Nutrition Examination Survey, 2003-2010.

Authors:  Emiko Y Petrosky; Susan Hariri; Lauri E Markowitz; Gitika Panicker; Elizabeth R Unger; Eileen F Dunne
Journal:  Int J Infect Dis       Date:  2015-01-14       Impact factor: 3.623

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.